The Phase II trial start for PR022 in Atopic Dermatitis (AD) is an expected but nevertheless very positive development for Realm Therapeutics. In our view, AD represents a significant commercial opportunity, as highlighted by the recent approvals and current sales projections for Pfizer’s EUCRISA® and Sanofi/Regeneron’s Dupixent® ($0.7bn and $3.5bn respectively by 2021). We look forward to top-line results in Q3 2018 with anticipation, and reiterate our highly positive stance on Realm Therapeuti ....
05 Dec 2017
N+1 Singer - Realm Therapeutics - Phase II trial start in Atopic Dermatitis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Realm Therapeutics - Phase II trial start in Atopic Dermatitis
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
05 Dec 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
The Phase II trial start for PR022 in Atopic Dermatitis (AD) is an expected but nevertheless very positive development for Realm Therapeutics. In our view, AD represents a significant commercial opportunity, as highlighted by the recent approvals and current sales projections for Pfizer’s EUCRISA® and Sanofi/Regeneron’s Dupixent® ($0.7bn and $3.5bn respectively by 2021). We look forward to top-line results in Q3 2018 with anticipation, and reiterate our highly positive stance on Realm Therapeuti ....